Nebulized Hypertonic Saline for Inpatient Use in COPD
Status: | Completed |
---|---|
Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
Therapuetic Areas: | Pulmonary / Respiratory Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/24/2017 |
Start Date: | October 2014 |
End Date: | January 30, 2017 |
Nebulized Hypertonic Saline for Inpatient Use in Chronic Obstructive Pulmonary Disease
A comparison of albuterol treatments using hypertonic saline (3%) versus standard saline
(0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale
scores after 4 treatments within 24 hours.
(0.9%) in patients with admitted patients COPD in regard to Modified Borg Dyspnea scale
scores after 4 treatments within 24 hours.
Hypothesis:
A clinically significant difference exists between albuterol treatments with nebulized 3%
saline versus standard saline, for improvements in the patient's modified Borg dyspnea score
during an acute exacerbation of COPD.Study
Population:
This study will involve 146 patients admitted to Doctors Hospital in Columbus, Ohio from
September 2014 through September 2015 with a clinical diagnosis of an acute exacerbation of
COPD, defined as an increase in the patient's dyspnea, cough, or change in sputum
consistency/volume/color from the patient's baseline during stable conditions.
Study Design:
Patients will be randomly assigned to 2.5 mg albuterol treatments with either normal saline,
as is the standard, or hypertonic saline.
Once the patient is enrolled, they will be randomly assigned to 2.5 mg albuterol treatments
with either normal saline, as is the standard, or hypertonic saline. They will then receive
the 2.5mg albuterol treatment, and saline solution as determined by the randomization plan
(Group 1 will receive 0.9% saline and Group 2 will receive 3% saline), every six hours for at
least the first 24 hours, with allowance for PRN (pro re nata= as needed) use every four
hours by patient request.
The patient's dyspnea will be evaluated prior to starting the treatment and after the
intervention period is completed using the Modified Borg Dyspnea Scale.
A clinically significant difference exists between albuterol treatments with nebulized 3%
saline versus standard saline, for improvements in the patient's modified Borg dyspnea score
during an acute exacerbation of COPD.Study
Population:
This study will involve 146 patients admitted to Doctors Hospital in Columbus, Ohio from
September 2014 through September 2015 with a clinical diagnosis of an acute exacerbation of
COPD, defined as an increase in the patient's dyspnea, cough, or change in sputum
consistency/volume/color from the patient's baseline during stable conditions.
Study Design:
Patients will be randomly assigned to 2.5 mg albuterol treatments with either normal saline,
as is the standard, or hypertonic saline.
Once the patient is enrolled, they will be randomly assigned to 2.5 mg albuterol treatments
with either normal saline, as is the standard, or hypertonic saline. They will then receive
the 2.5mg albuterol treatment, and saline solution as determined by the randomization plan
(Group 1 will receive 0.9% saline and Group 2 will receive 3% saline), every six hours for at
least the first 24 hours, with allowance for PRN (pro re nata= as needed) use every four
hours by patient request.
The patient's dyspnea will be evaluated prior to starting the treatment and after the
intervention period is completed using the Modified Borg Dyspnea Scale.
Inclusion Criteria:
- Patients at least 18 years of age
- Admitted to Doctors Hospital with a clinical diagnosis of COPD
- Documented obstruction on spirometry from prior records available at the time of the
study.
Exclusion Criteria:
- Patients younger than 18 years of age
- Spirometry data not available
- History of smoking less than twenty pack-years
- Possibility of other primary cause of the patient's change in dyspnea or cough (e.g.
pneumonia, congestive heart failure with pulmonary edema, myocardial infarction)
- Patient is found to have a different primary cause after initial enrollment
- Non-English speaking subjects
We found this trial at
1
site
5100 W Broad St
Columbus, Ohio 43228
Columbus, Ohio 43228
(614) 544-1000
Principal Investigator: Kruti Patel, DO
Phone: 614-544-1923
Doctors Hospital Nationally recognized for care quality and patient safety and satisfaction, Doctors Hospital is...
Click here to add this to my saved trials